This report looks at the evidence collected and assessed by the Safety Monitoring Committee established to assess whether there were adverse outcomes following the introduction of new NHMRC guidelines on how women with a low-grade Pap test result or a treated high-grade cervical biopsy result should be managed.
Acknowledging that new evidence may come to light in future which could affect this picture, the overarching message from the evidence currently available and the methods used to assess this evidence is that the new guidelines have not led to an increase in cervical cancer in the seven years since they were introduced.
ISSN 1039-3307; ISBN 978-1-74249-515-6; Cat. no. CAN 77; 52pp.; $12
Publication table of contents
- Preliminary material
- Title and verso pages
- Body section
- 1 Introduction
- 1.1 Why have guidelines?
- 1.2 Why monitor the safety of these guidelines?
- 1.3 How has the safety of the guidelines been monitored?
- 2 Consideration of background trends in cervical abnormalities and cancer
- 2.1 Cervical abnormalities detected by cytology
- 2.2 Cervical abnormalities detected by histology
- 2.3 Women with high-grade abnormalities detected by histology (high-grade abnormality
- detection rate)
- 2.4 Cervical cancer incidence
- 3 Outcomes of projects to assess the safety of the guidelines
- 3.1 Are women with a pre-invasive cervical abnormality more likely to be diagnosed with a
- subsequent cervical cancer since the introduction of the guidelines?
- 3.3 What did the review of cervical cancer cases included in the analyses reveal?
- 3.4 What did the survey of pathology laboratories reporting cervical cytology show?
- 3.5 What did the compliance study reveal?
- 4 Discussion
- End matter
- Appendix A Additional tables
- Appendix B Data sources
- Appendix C Data quality statement: Cervical screening safety monitoring data
- Appendix D Statistical methods
- List of tables
- List of figures
AIHW 2013. Report on monitoring activities of the National Cervical Screening Program Safety Monitoring Committee. Cancer series 80. Cat. no. CAN 77. Canberra: AIHW.